Mycobacterium tuberculosis infection continues to have a high incidence rate and remains the second leading cause of death due to infectious agents worldwide. During the Covid-19 pandemic, tuberculosis (TB) patients have faced significant social stigma as their symptoms closely resemble those of Covid-19. Consequently, many TB patients have been reluctant to undergo routine evaluations and have avoided meeting with healthcare providers. This situation is further exacerbated by the policies restricting in-person meetings and the increased number of hospitals designated as Covid-19-only facilities, leading to challenges in conducting regular check-ups for patients with other infectious diseases, such as TB. These circumstances have also posed difficulties in controlling TB cases during the Covid-19 pandemic.

This comprehensive and informative book serves as a valuable resource for healthcare professionals, researchers, policymakers, and anyone interested in advancing the field of TB management during the challenging times of the Covid-19 pandemic. It provides a fresh perspective on the intersection of infectious diseases and sheds light on the potential of innovative therapies to combat Mycobacterium tuberculosis and protect the host defense system.